Jagiellonian University Repository
Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf "unlimited" therapeutic agent : results from the Acute Myocardial Infarction First-in-Man Study
Communities & Collections
pcg.skipToMenu
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa
Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf "unlimited" therapeutic agent : results from the Acute Myocardial Infarction First-in-Man Study
Bibliographic description
| title: | Myocardial regeneration strategy using Wharton's jelly mesenchymal stem cells as an off-the-shelf "unlimited" therapeutic agent : results from the Acute Myocardial Infarction First-in-Man Study |
| author: | Musiałek Piotr  , Mazurek Adam, Jarocha Danuta , Tekieli Łukasz, Szot Wojciech , Kostkiewicz Magdalena , Banyś Robert Paweł, Urbanczyk Malgorzata, Kądzielski Andrzej, Trystuła Mariusz , Kijowski Jacek , Żmudka Krzysztof , Podolec Piotr , Majka Marcin
|
| journal title: | Postępy w Kardiologii Interwencyjnej |
| volume: | 11 |
| issue: | 2 (40) |
| date of publication : | 2015 |
| pages: | 100-107 |
| ISSN: |
1734-9338 |
| eISSN: |
1897-4295 |
| DOI: | |
| language: | English |
| journal language: | English |
| abstract in English: | Introduction: In large-animal acute myocardial infarction (AMI) models, Wharton’s jelly (umbilical cord matrix) mesenchymal stem cells (WJMSCs) effectively promote angiogenesis and drive functional myocardial regeneration. Human data are lacking. Aim: To evaluate the feasibility and safety of a novel myocardial regeneration strategy using human WJMSCs as a unique, allogenic but immuno-privileged, off-the-shelf cellular therapeutic agent. Material and methods: The inclusion criterion was first, large (LVEF ≤ 45%, CK-MB > 100 U/l) AMI with successful infarct-related artery primary percutaneous coronary intervention reperfusion (TIMI ≥ 2). Ten consecutive patients (age 32–65 years, peak hs-troponin T 17.3 ±9.1 ng/ml and peak CK-MB 533 ±89 U/l, sustained echo LVEF reduction to 37.6 ±2.6%, cMRI LVEF 40.3 ±2.7% and infarct size 20.1 ±2.8%) were enrolled. Results: 30 × 106 WJMSCs were administered (LAD/Cx/RCA in 6/3/1) per protocol at ≈ 5–7 days using a cell delivery dedicated, coronary-non-occlusive method. No clinical symptoms or ECG signs of myocardial ischemia occurred. There was no epicardial flow or myocardial perfusion impairment (TIMI-3 in all; cTFC 45 ±8 vs. 44 ±9, p = 0.51), and no patient showed hs-troponin T elevation (0.92 ±0.29 ≤ 24 h before vs. 0.89 ±0.28 ≤ 24 h after; decrease, p = 0.04). One subject experienced, 2 days after cell transfer, a transient temperature rise (38.9°C); this was reactive to paracetamol with no sequel. No other adverse events and no significant arrhythmias (ECG Holter) occurred. Up to 12 months there was one new, non-index territory lethal AMI but no adverse events that might be attributable to WJMSC treatment. Conclusions: This study demonstrated the feasibility and procedural safety of WJMSC use as off-the-shelf cellular therapy in human AMI and suggested further clinical safety of WJMSC cardiac transfer, providing a basis for randomized placebo-controlled endpoint-powered evaluation. |
| keywords in English: | myocardial regeneration, Wharton’s jelly mesenchymal stem cells, human umbilical cord matrix, acute myocardial infarction, first-in-man, safety, feasibility |
| departmental parameterization: | 15 |
| affiliation: | Wydział Lekarski : Instytut Kardiologii, Wydział Lekarski : Instytut Pediatrii |
| type: | journal article |
| subtype: | academic paper |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach 4.0 Międzynarodowa
Projekt „Repozytorium otwartego dostępu do dorobku naukowego i dydaktycznego UJ” współfinansowany w ramach poddziałania 2.3.1 „Cyfrowe udostępnianie zasobów nauki” Programu Operacyjnego Polska Cyfrowa z Europejskiego Funduszu Rozwoju Regionalnego i budżetu państwa na podstawie umowy o dofinansowanie nr POPC.02.03.01-00-0030/17-00
